Aktienanalyse zu Turn Therapeutics Inc (TTRX)TTRXTurn Therapeutics Inc

Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis. It operates in the Healthcare sector.

Turn Therapeutics Inc. (TTRX) is a good buy right now, as it is currently priced at $10.28, significantly lower than the analyst price target of $24, indicating a potential upside of 134%. Additionally, the recent Phase 2 trial results for GX-03 show that 92.6% of participants achieved a 50% reduction in eczema severity, which could drive future revenue growth. The main risk is the company's high debt to equity ratio of 882.68%, which indicates significant financial leverage and potential vulnerability.